Pulmonary vein myocardium as a possible pharmacological target of atrial fibrillation

DOI Web Site Web Site PubMed 被引用文献6件 参考文献33件 オープンアクセス
  • Takahara Akira
    Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Toho University, Japan
  • Hagiwara Mihoko
    Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Toho University, Japan
  • Namekata Iyuki
    Department of Pharmacology, Faculty of Pharmaceutical Sciences, Toho University, Japan
  • Tanaka Hikaru
    Department of Pharmacology, Faculty of Pharmaceutical Sciences, Toho University, Japan

書誌事項

タイトル別名
  • Pulmonary Vein Myocardium as a Possible Pharmacological Target for the Treatment of Atrial Fibrillation

この論文をさがす

抄録

The pulmonary vein has a unique electrophysiological property showing an autonomic electrical activity, and this phenomenon has been further focused on as a source of triggers of atrial fibrillation. The pulmonary vein cardiomyocytes have shorter action potential duration, less negative resting membrane potential, and smaller maximum upstroke velocity than those in the left atrium, whose underlying cellular mechanisms may generate arrhythmogenic substrates such as abnormal automaticity and triggered activity. In diseased conditions including sustained atrial tachycardia or chronic volume overload, its arrhythmogenic profile can be further modified through abbreviation of action potential duration of the pulmonary vein myocardium, which may become a cause of reentry. Recently, antiarrhythmic effects of various drugs have been extensively investigated in isolated pulmonary vein preparations. The present review article highlights the recent advances in our understanding of electrophysiological and pharmacological profiles of the pulmonary vein.

収録刊行物

被引用文献 (6)*注記

もっと見る

参考文献 (33)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ